W2.2 Viral vectored vaccine platform technologies

W9.2 Evidence and Lessons Learned on Social Sciences Analytics around Vaccination

W6.1 Vaccine Development to Access: Opportunities, risks and potential valleys of death

W6.3 Building the concept of WHO Vaccine Preferred Policy Profiles

W1.3 Not enough to go around: vaccine manufacturing for the COVID-19 pandemic

W2.1 Nucleic acid vaccines: Is it all done?

W3.3 Considerations for mass deployment of innovative vaccines in low- and middle-income country immunization programs

W2.4 Universal Influenza Vaccines

P2.1 Current status and future prospects for human immunodeficiency virus (HIV) vaccines

P1.2 Rapid Response Platforms for COVID-19 Vaccine

W4.1 Controlled human malaria infection — tool for accelerating vaccine development

W5.2 Schistosomiasis vaccines, development and role in elimination

P3.2 Impact of COVID-19 on coverage and equity

W5.1 Salmonella typhi vaccines, development and deployment

W6.2 Vaccine development to access: Is there a role for earlier policy consideration?

W7.1 Protection of newborn infants through vaccination

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

Agenda - GVIRF 2021

W3 Innovation in Vaccination

W9 Building and Sustaining Uptake

W4 Controlled Human Infection Models for Vaccine Research and Development

P2 HIV, TB & Malaria Vaccine Update

P2 HIV, TB & Malaria Vaccine Update

P2 HIV, TB & Malaria Vaccine Update

W5 New and Improved Vaccines on the Horizon

W9.1 Building and Sustaining Uptake: Summary of the latest evidence and open research questions

W2.3 Adjuvants for use in subunit-based vaccines and global access focus on licensed one

P1 Epidemic and Pandemic Preparedness and Response

W1 Innovations in Vaccine Manufacturing

KN3 Research for Equity

P3.1 The enduring dilemma of 20 million unvaccinated children: Equity and access solutions in IA2030

P3 Shaping the Future: Equitable Access for All

KN2 The Lessons of COVID-19 for Vaccine Development

W2.3 Adjuvants

W5.3 Single-dose HPV Vaccination

W1.2 Vaccine Manufacturing at Lab Scale: A paradigm shift to more affordable vaccines

P1.1 Research during outbreak response: from Ebola to the COVID-19 pandemic

W9.3 Building and Sustaining Uptake: Case study the Philippines

W5.4 Improved vaccines: Novel oral polio vaccine (OPV)

W4.2 Typhoid controlled human infection model

Introduction to GVIRF

P2.2 Update on progress in tuberculosis vaccine development

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

KN1 Vaccinology in the context of pandemic preparedness: The COVID-19 experience

KN2.2 Innovating from Research to Impact at Scale: the role of the Gavi Alliance

W2 Emerging Platforms

W6 Vaccine Development to Access

W8 Prioritization for Vaccine R&D

P1.3 Rapid (and precise) COVID-19 Vaccine Development Enabled by Prototype Pathogen Preparedness

KN3 Research for Equity - VIDEO

*Meeting Summary: Global Vaccine and Immunization Research Forum, 2021